Seeking Alpha

bhorgan

bhorgan
Send Message
View as an RSS Feed
View bhorgan's Comments BY TICKER:
Latest  |  Highest rated
  • Amarin: How Cost Cutting Affects Cash Burn And Profitability [View article]
    How did you handle the sales discount program? I believe these costs are being put into selling expense and since they have committed to continuing the program wouldn't this increase the overhead significantly? They also noted that due to lower expected scrips they will be making payments to the suppliers to cover for the production loss (10Q) how did you factor in these increases?
    Nov 15, 2013. 10:44 PM | Likes Like |Link to Comment
  • Amarin Investor Discontent Turns To Mutiny [View article]
    JZ and the boys won't sell the company only partner because they know damn well that once a BO is offered (knowing that it will be well below fair value) the lawyers will come out of the woodwork to file class action lawsuits for breach of fiduciary duty and they will win. That is also why you will never see any proof of a buyout offer and if there ever was then those documents have been shredded. The only way for them to possibly avoid this is to take a partner (of course it will be more favorable for the partner) which will automatically bump up pps and JZ and boys will then bolt like thieves in the night.
    Nov 1, 2013. 08:06 PM | Likes Like |Link to Comment
  • Did The FDA Just Issue Amarin's Death Blow Again? [View article]
    I believ thhat was ARNA
    Oct 30, 2013. 08:42 PM | Likes Like |Link to Comment
  • Did The FDA Just Issue Amarin's Death Blow Again? [View article]
    you need to look at press releases on the company website, I believe it was in Feb 2012
    Oct 30, 2013. 08:42 PM | Likes Like |Link to Comment
  • Did The FDA Just Issue Amarin's Death Blow Again? [View article]
    I looked through every press release they had and found no information on them filing with the EMA. However I did see where they recieved a patent in Europe
    Oct 30, 2013. 04:06 PM | Likes Like |Link to Comment
  • Did The FDA Just Issue Amarin's Death Blow Again? [View article]
    People should be pointing the finger at AMRN management who did not provide an adequate salesforce nor seek approval in Europe or Asia to market V and expand the market. In the meantime they avoided questions on marketing strategy by saying it's to early or we don't want to give our competion (or our shareholder's) any idea about what we are doing (acting as if they had some new brilliant strategy that BP wouldn't have figured out by now).What amazes me is that they haven't been sued for lack of fiduciary responsibility. What company in there right mind and with such limited resources sign up for a 3-5 year test using shareholder money and not having a legal binding document to re-coupe some of the cost if not approved especially if a SPA becomes void if there is changes in science (especially when there are other companies working on different products that have the same results). So management was unaware of this sentence in the FDA guidlines and was willing to risk milions of shareholder $ on a program that in the end will result in no return.
    Oct 30, 2013. 03:23 PM | 3 Likes Like |Link to Comment
  • A Stock That May Rally $20 In 3-Months [View instapost]
    I really do enjoy reading your articles Steve. I have a couple of questions

    1). Why do you think the company diluted so far in advance of Anchor PDUFA.
    2). Was it required that they issue an 8k with Reduce-it enrollment - At this point I don't understand why they did and I don't remember seeing previous 8k.
    3). Why do you think BP hasn't already purchased AMRN? Wouldn't it be better to acquire before anchor?
    4)Is it possible that the NCE delay could be linked to anchor and that AF may actually be correct and the FDA does want more data before approval. I understand they have a SPA but it kinda seems that the FDA does whatever the hell they want and when they want.

    Again thanks for your posts
    Sep 30, 2013. 09:38 PM | Likes Like |Link to Comment
  • It's All About Anchor  [View instapost]
    steve,

    how can you maintain a $28-$30 BO price when they increased the shares by 20M. that would mean your previous target would have to be $32-$35.
    Jul 10, 2013. 11:58 AM | 1 Like Like |Link to Comment
  • Amarin's Anchor Will Hold As Vascepa's Sails Unfurl [View article]
    It's nice to read a article that is positive every now and then
    Jun 21, 2013. 07:46 AM | 2 Likes Like |Link to Comment
  • Amarin: The Bull Argument (Or How I Learned To Stop Worrying And Love Vascepa) [View article]
    nice article
    May 1, 2013. 02:21 AM | Likes Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout [View article]
    Welcome back - Can you start a new feed this one is slowing down my computer
    Jan 31, 2013. 03:25 AM | 1 Like Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout [View article]
    If AMRN needs to do 5-10m this qtr. to meet analyst estimates does that include the initial stocking of the shelves or does it become a sale when there is a RX?
    Jan 21, 2013. 08:31 AM | Likes Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout [View article]
    I enjoy your insight , timing isn't perfect but that's completely understandable.

    Thank you
    Dec 12, 2012. 03:24 AM | Likes Like |Link to Comment
COMMENTS STATS
12 Comments
8 Likes